Lynparza is the first targeted medicine to show clinical benefit in the adjuvant setting for patients with germline BRCA-mutated high-risk HER2-negative early breast cancer
Calquence shows sustained four-year clinical benefit in 1st-line chronic lymphocytic leukaemia and lower atrial fibrillation rates in previously treated patients vs. ibrutinib
Imfinzi five-year data represent longest-ever survival reported in a Phase III immunotherapy trial in unresectable Stage III lung cancer
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
